On Dec. 7, 2020, Chimerix announced the U.S. Food and Drug Administration (FDA) had accepted the filing of a New Drug Application (NDA) for brincidofovir (BCV) as a medical countermeasure for smallpox. The FDA granted Priority Review and set an action date of April 7, 2021 under the Prescription Drug User Fee Act.

This milestone initiated the review process for the oral antiviral, leading to its eventual approval as Tembexa in June 2021 for the treatment of smallpox in adult and pediatric patients.

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Their three most advanced clinical-stage development programs are brincidofovir (BCV), ONC201 and dociparstat sodium (DSTAT). BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox